Cheryl Pegus, who serves as a director at Boston Scientific Corp (NASDAQ:BSX), recently executed an insider purchase of the company's common stock. On May 20, 2026, Ms. Pegus acquired 1,770 shares of the corporation’s common stock, totaling $99,987 in value.
The acquisition was conducted at varying prices, ranging from a low of $56.49 to a high of $56.5009 per share. Based on these transactions, the weighted average purchase price for the shares was determined to be $56.49 per share. Following this transaction, Ms. Pegus's direct holdings in Boston Scientific common stock increased by 1,770 shares.
The disclosure of this insider buying activity was formalized through a Form 4 filing submitted to the U.S. Securities and Exchange Commission on May 21, 2026.
This recent purchase comes as Boston Scientific shares have experienced a decline of 46% over the preceding year. As of the time of reporting, the stock was trading at $57.15. Despite this market movement, an analysis from InvestingPro suggested that the stock might be undervalued, citing its Fair Value assessment and noting that the company maintains a